BMS Archive

Plant · Scientific monograph

Serenoa repens

Saw Palmetto

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Prostate & Urological Research, Androgen Research, Inflammatory Pathways

Research overview

Historical use

Serenoa repens (saw palmetto) is native to the southeastern United States and was used extensively by Native American peoples (including the Seminole) as a food staple and for urinary conditions, reproductive health, and as a general tonic. European physicians adopted it in the late 19th century for urinary symptoms and prostate complaints. Liposterolic extract of Serenoa repens (LESP) was one of the first herbal medicines to enter modern European pharmacopoeia for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Modern research context

A 2012 Cochrane systematic review of 32 RCTs (n=5,666) found that Serenoa repens did not improve urinary flow rates or prostate size versus placebo — results were consistent across doses up to three times the standard dose [1]. The landmark CAMUS trial (n=369, 72 weeks, JAMA 2011) confirmed no statistically significant difference between saw palmetto 320 mg, 640 mg, 960 mg/day and placebo on AUASI, Qmax, PSA, or prostate volume [2]. These high-quality trials supersede older positive results from smaller, less rigorous studies. Despite negative RCT data, in vitro studies consistently demonstrate 5α-reductase type I and II inhibition, α1-adrenergic receptor antagonism, and anti-inflammatory (COX-1/2) activity at relevant concentrations [3]. The disconnect between in vitro mechanism and clinical trial results remains unexplained; bioavailability and extract standardisation variability may contribute [4]. A 2008 review concluded saw palmetto is comparable to tamsulosin for symptom scores in mild LUTS but inferior to finasteride for prostate volume reduction [3].

Adverse effects

Generally very well-tolerated. Most common adverse effects in trials: headache, nausea, gastrointestinal upset, dizziness, and fatigue — at frequencies comparable to placebo in the CAMUS trial [2]. Rare case reports of hepatotoxicity and pancreatitis; causality unestablished. No significant effects on PSA, testosterone, or oestradiol at standard doses in controlled trials.

Contraindications

Hormone-sensitive conditions — theoretical 5α-reductase activity may affect androgen levels; caution in prostate cancer until further evidence. Concurrent use with finasteride or dutasteride — additive 5α-reductase inhibition, uncharacterised interaction. Anticoagulants (warfarin) — case reports of potentiation; monitor INR [3, 4]. Insufficient safety data in pregnancy and lactation — avoid.

Clinical and phytochemical data

Used part

Ripe dried fruit; lipophilic extract (hexane or supercritical CO₂)

Primary active compounds

  • Free fatty acids: lauric acid, oleic acid, myristic acid, palmitic acid (primary active lipid fraction)

  • Phytosterols: β-sitosterol, campesterol, stigmasterol

  • Monoglycerides and diglycerides

  • Flavonoids: isoquercitrin, kaempferol glycosides

  • Polysaccharides (water-soluble fraction; immunostimulatory)

Mechanism of action

5α-Reductase inhibition (types I and II): Lipophilic extract non-competitively inhibits both isoforms of 5α-reductase, reducing intraprostatic dihydrotestosterone (DHT) production. α1-Adrenergic antagonism: Reduces smooth muscle tone in the prostate stroma and bladder neck, improving urine flow. Anti-inflammatory: Inhibits COX-1 and COX-2 pathways and reduces NF-κB-mediated cytokine production (TNF-α, IL-1β). Anti-proliferative: Induces apoptosis in prostatic epithelial cells via androgen receptor pathway downregulation [3, 4].

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Lipophilic extract is absorbed via lymphatic route; fatty acids achieve higher plasma concentrations when taken with food (fat-soluble). The liposterolic fraction shows pH-dependent dissolution.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Phytosterols and fatty acids distribute to adipose tissue, liver, and prostate gland. β-Sitosterol is incorporated into cell membranes and competes with cholesterol for absorption at the intestinal brush border.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Free fatty acids undergo standard β-oxidation. Phytosterols are poorly metabolised and largely excreted unchanged. Minimal CYP450 interaction data available.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Phytosterols excreted primarily in bile/faeces. Water-soluble metabolites excreted renally.

Safety and interactions

Drug interactions

Warfarin and antiplatelet drugs — case reports of INR potentiation; monitor coagulation parameters. Finasteride/dutasteride — additive 5α-reductase inhibition; combination not studied in clinical trials. Hormone therapies (testosterone, oestrogen) — theoretical pharmacodynamic interaction via androgen pathway effects [3].

Toxicity

No significant safety signals in the CAMUS trial at doses up to 960 mg/day over 72 weeks [2]. Rare case reports of hepatotoxicity, pancreatitis, and intraoperative floppy iris syndrome — causality not established. No known genotoxicity or carcinogenicity.

Special precautions

Pregnancy

Avoid — 5α-reductase inhibition may affect foetal androgen-dependent development.

Lactation

No human clinical safety data are available during lactation. Saw palmetto's 5α-reductase inhibitory and anti-androgenic activity may theoretically affect the hormonal milieu required to sustain lactation; prolactin suppression is a theoretical concern. Avoid during breastfeeding due to insufficient safety data and potential hormonal interference.

Hepatic impairment

Rare hepatotoxicity case reports. Monitor LFTs with prolonged use in patients with pre-existing liver disease.

Renal impairment

No specific data. Standard dose precautions apply.

Sources and references

  1. [1] - Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ., "Serenoa repens for benign prostatic hyperplasia.", Cochrane Database Syst Rev, 2012, PMID: 22236618
  2. [2] - Barry MJ, Meleth S, Lee JY et al., "Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial (CAMUS).", JAMA, 2011, PMID: 21209401
  3. [3] - Dedhia RC, McVary KT., "Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.", J Urol, 2008, PMID: 18220013
  4. [4] - Habib FK, Wyllie MG., "Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract.", Prostate Cancer Prostatic Dis, 2004, PMID: 15452574
  5. [5] - Gerber GS, Kuznetsov D, Johnson BC, Berger JD., "Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms.", Urology, 2001, PMID: 11257693

Additional source links

Continue browsing